The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
Open accessAbstract
PURPOSE: This phase I clinical trial evaluated the safety, tolerability, and pharmacokinetics of high-dose intravenous (i.v.) ascorbic acid as a monotherapy in patients with advanced solid tumors refractory to standard therapy. METHODS: Five cohorts of three patients received i.v. ascorbic acid administered at 1 g/min for 4 consecutive days/week for 4 weeks, starting at 30 g/m² in the first cohort. For subsequent cohorts, dose was increased by 20 g/m² until a maximum tolerated dose was found. RESULTS: Ascorbic acid was eliminated by simple first-order kinetics. Half-life and clearance values were similar for all patients of all cohorts (2.0 ± 0.6 h, 21 ± 5 dL/h m², respectively). C(max) and AUC values increased proportionately with dose between 0 and 70 g/m², but appeared to reach maximal values at 70 g/m² (49 mM and 220 h mM, respectively). Doses of 70, 90, and 110 g/m² maintained levels at or above 10-20 mM for 5-6 h. All doses were well tolerated. No patient demonstrated an objective antitumor response. CONCLUSIONS: Ascorbic acid administered i.v. at 1 g/min for 4 consecutive days/week for 4 weeks produced up to 49 mM ascorbic acid in patient's blood and was well tolerated. The recommended dose for future studies is 70-80 g/m².
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Chen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Shacter, E., & Levine, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506390102 · Cited by 1,075
Kennedy, C. O. (1971) · British Homeopathic Journal · doi:10.1016/s0007-0785(71)80027-3 · Cited by 974
Cameron, E., & Pauling, L. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.10.3685 · Cited by 710
Moertel, C. G., Fleming, T. R., Creagan, E. T., Rubin, J., O'Connell, M. J., & Ames, M. M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198501173120301 · Cited by 637
Creagan, E. T., Moertel, C. G., O'Fallon, J. R., Schutt, A. J., O'Connell, M. J., Rubin, J., & Frytak, S. (1979) · New England Journal of Medicine · doi:10.1056/nejm197909273011303 · Cited by 584
Cocks, K., King, M. T., Velikova, G., de Castro, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.059 · Cited by 552
Groenvold, M., Klee, M. C., Sprangers, M. A. G., & Aaronson, N. K. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00428-3 · Cited by 482
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy
Hoffer, L. J., Levine, M., Assouline, S., Melnychuk, D., Padayatty, S. J., Rosadiuk, K., Rousseau, C., Robitaille, L., & Miller, W. H. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn377 · Cited by 375
Hjermstad, M. J., Fossa, S. D., Bjordal, K., & Kaasa, S. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1249 · Cited by 371
Cameron, E., & Campbell, A. (1974) · Chemico-Biological Interactions · doi:10.1016/0009-2797(74)90019-2 · Cited by 344
Monti, D. A., Mitchell, E., Bazzan, A. J., Littman, S., Zabrecky, G., Yeo, C. J., Pillai, M. V., Newberg, A. B., Deshmukh, S., & Levine, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029794 · Cited by 274
Intravenously administered vitamin C as cancer therapy: three cases
Padayatty, S. J. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050346 · Cited by 252
Kurbacher, C. M., Wagner, U., Kolster, B., Andreotti, P. E., Krebs, D., & Bruckner, H. W. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04212-7 · Cited by 235
Verrax, J., & Calderon, P. B. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.02.016 · Cited by 230
Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs
Heaney, M. L., Gardner, J. R., Karasavvas, N., Golde, D. W., Scheinberg, D. A., Smith, E. A., & O'Connor, O. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1490 · Cited by 227
Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer
Espey, M. G., Chen, P., Chalmers, B., Drisko, J., Sun, A. Y., Levine, M., & Chen, Q. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.03.007 · Cited by 190
Vitamin C preferential toxicity for malignant melanoma cells
Bram, S., Froussard, P., Guichard, M., Jasmin, C., Augery, Y., Sinoussi-Barre, F., & Wray, W. (1980) · Nature · doi:10.1038/284629a0 · Cited by 189
Maramag, C., Menon, M., Balaji, K. C., Reddy, P.-V., & Laxmanan, S. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970801)32:3<188::aid-pros5>3.0.co;2-h · Cited by 158
The orthomolecular treatment of cancer
Cameron, E., Campbell, A., & Jack, T. (1975) · Chemico-Biological Interactions · doi:10.1016/0009-2797(75)90007-1 · Cited by 124
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients.
Riordan, H. D., Casciari, J. J., González, M. J., Riordan, N. H., Miranda-Massari, J. R., Taylor, P. R., & Jackson, J. A. (2005) · PubMed · Cited by 116
Reevaluation of Ascorbate in Cancer Treatment: Emerging Evidence, Open Minds and Serendipity
Padayatty, S. J., & Levine, M. (2000) · Journal of the American College of Nutrition · doi:10.1080/07315724.2000.10718941 · Cited by 102
Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours
Casciari, J. J., Riordan, N. H., Schmidt, T. L., Meng, X., Jackson, J. A., & Riordan, H. D. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1814 · Cited by 101
The orthomolecular treatment of cancer I. The role of ascorbic acid in host resistance
Cameron, E., & Pauling, L. C. (1974) · Chemico-Biological Interactions · doi:10.1016/0009-2797(74)90018-0 · Cited by 99
Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines.
Leung, P. Y., Miyashita, K., Young, M., & Tsao, C. S. (1993) · PubMed · Cited by 91
Murata, A., Morishige, F., & Yamaguchi, H. (1982) · PubMed · Cited by 74
Losing and finding a way at C: New promise for pharmacologic ascorbate in cancer treatment
Levine, M., Espey, M. G., & Chen, Q. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.04.001 · Cited by 67
Intravenous vitamin C as a chemotherapy agent: a report on clinical cases.
Riordan, H. D., Riordan, N. H., Jackson, J. A., Casciari, J. J., Hunninghake, R., González, M. J., Mora, E., Miranda-Massari, J. R., Rosario, N., & Rivera, A. (2004) · PubMed · Cited by 55
On the physiological action of ascorbic acid and some related compounds
Demole, V. (1934) · Biochemical Journal · doi:10.1042/bj0280770 · Cited by 54
Jamison, J. M., Gilloteaux, J., Nassiri, M. R., Venugopal, M., Neal, D. R., & Summers, J. L. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.08.040 · Cited by 52
Intravenous ascorbic acid: protocol for its application and use.
Riordan, H. D., Hunninghake, R., Riordan, N. H., Jackson, J. J., Meng, X., Taylor, P. B., Casciari, J. J., González, M. J., Miranda-Massari, J. R., Mora, E., et al. (2003) · PubMed · Cited by 47
No Contribution of Ascorbic Acid to Renal Calcium Oxalate Stones
GERSTER, H. (1997) · Annals of Nutrition and Metabolism · doi:10.1159/000177954 · Cited by 41
Makino, Y., Sakagami, H., & Takeda, M. (2000) · PubMed · Cited by 33
Munkres, K. D. (1979) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(79)90039-3 · Cited by 29
Cullen, J. J., Spitz, D. R., & Buettner, G. R. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.03.030 · Cited by 10
Cited by
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock
Marik, P. E., Khangoora, V., Rivera, R., Hooper, M. H., & Catravas, J. (2017) · Chest · doi:10.1016/j.chest.2016.11.036 · Cited by 887
The Pharmacokinetics of Vitamin C
Lykkesfeldt, J., & Tveden-Nyborg, P. (2019) · Nutrients · doi:10.3390/nu11102412 · Cited by 344
TET (Ten-eleven translocation) family proteins: structure, biological functions and applications
Zhang, X., Zhang, Y., Wang, C., & Wang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01537-x · Cited by 273
Iron and thiol redox signaling in cancer: an exquisite balance to escape ferroptosis
Toyokuni, S., Ito, F., Yamashita, K., Okazaki, Y., & Akatsuka, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.024 · Cited by 252
Metadata
- Authors
- Stephenson, C. M., Levin, R. D., Spector, T., & Lis, C. G.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2013-05-14
- Volume
- 72
- Issue
- 1
- Pages
- 139-146
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2160014667
- Cited by
- 264
- References
- 36
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.